Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Breast Cancer

NCT00499525 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT00499525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00499525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Breast Cancer
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2007
Completion date
December 31, 2022
Enrollment
180 (estimated)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer